Open AccessAutologous mesenchymal stem cells and cutaneous autograft as a treatment for chronic ulcer secondary to diabetes mellitus 2
Author(s) -
Gamaliel Benítez-Arvizu,
Ícela Palma-Lara,
René Vazquez-Campos,
Raimundo Alfonso Sesma-Villalpando,
Alberto ParraBarrera,
Gisela Gutiérrez-Iglesias
Publication year - 2015
Publication title -
cirugía y cirujanos
Language(s) - English
Resource type - Journals
ISSN - 2444-0507
DOI - 10.1016/j.circen.2015.11.010
Subject(s) - medicine , diabetes mellitus , myocardial infarction , type 2 diabetes mellitus , mesenchymal stem cell , population , stem cell , surgery , pathology , endocrinology , environmental health , biology , genetics
BackgroundDiabetes mellitus 2 has become a global problem. It is estimated that 15–25% of patients could develop a chronic ulcer in their life, and nearly 33% of direct care costs of the diabetes mellitus 2 is spent on treating these ulcers. Mesenchymal stem cells have emerged as a promising cell source for the treatment of these ulcers.Clinical caseThe case is presented of a 67 year-old male with a history of diabetes mellitus, acute myocardial infarction, and chronic ulcer involving right foot and part of his leg. He was treated with mesenchymal stem cell management, resulting in skin graft integration and full coverage of the lesion.ConclusionThe implementation of mesenchymal stem cell techniques for treatment of chronic ulcer is feasible. The impact on the population would lead to a significant improvement in their quality of life and reduce healthcare spending